Is BioInvent International AB (publ) (BOVNF) a Buy, Sell, or Hold?
OTC : BOVNF
BioInvent International AB (publ)
$3.2886 USD
$0 (0.0%)
- Volume
- 908
- Average Volume
- 797
- Market Capitalization
- $216.4M
- P/E Ratio
- -4.42
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $4.70
- Year Low
- $3.29
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $5.32
Company Overview
OTC
Martin Welschof
Biotechnology
Healthcare
BOVNF
114
SE
USD
Liquidity Metrics
0.01
5.32
5.20
3.75
0.00
Sales & Valuation
$225.93M
6.80
3.38
-5.57
-4.03
Profitability
-$5.07
-$332.02M
-153.98%
-153.78%
-53.88%
-62.71%
P/E Metrics
-4.42
-0.24
-0.24
Analyst Price Target & Rating
2/5
0 Analysts
%
Financial Health Scores
12.34
2/9
$410.58M
$534.96M
$95.85M
-$344.46M
Key Metrics (TTM)
$1.11B
5.10
-3.40
5.32
-53.88%
-78.78%
-22.94%
-18.19%
63 days
Company Executives
| Name | Title |
|---|---|
| Kristoffer Rudenholm Hansson | Senior Vice President of Technical Operations |
| Ingrid Teige | Head of Preclinical Research |
| Sylvie Ryckebusch | Chief Business Officer |
| Andres McAllister | Chief Medical Officer |
| Stefan Ericsson | Chief Financial Officer |
| Ashley R. Robinson | Senior VP of Strategy & Finance |
| Björn Frendéus | Chief Scientific Officer |
| Ingunn Munch Lindvig | Senior Vice President of Regulatory Affairs |
| Cecilia Hofvander | Vice President of Investor Relations |
| Martin Welschof | President & Chief Executive Officer |
Poll Results
No votes yet today — be the first to share your view!
About BioInvent International AB (publ) (OTC:BOVNF) Stock
BioInvent International AB (publ) is a clinical-stage biotechnology company primarily focused on identifying, exploring, and engineering immunomodulatory antibodies to combat various forms of cancer. The company's activities extend globally, reaching markets in Sweden, across Europe, the United States, Japan, and other international regions. Its leading investigational compound is BI-1206, which is being developed to address both non-Hodgkin lymphoma and a range of solid tumors. Beyond this flagship program, BioInvent is advancing a diverse pipeline of therapeutic candidates. These include agents designed to target tumor-associated myeloid cells and cancer-associated regulatory T cells, which play a vital role in regulating the immune system. The company's portfolio also features BT-001 fo ... r solid tumor indications, as well as BI-1808 and BI-1910 – both anti-TNFR2 antibodies specifically intended for the treatment of solid tumors and cutaneous T-cell lymphoma. To further its development initiatives, BioInvent has established several key collaborations. It maintains a strategic alliance with Pfizer Inc. for the development of antibodies targeting tumor-associated myeloid cells. The company also collaborates with Transgene to jointly create innovative multi-functional oncolytic viruses aimed at solid tumors. Additionally, a collaboration and supply agreement with Merck facilitates the clinical advancement of BI-1808. Founded in 1996, BioInvent International AB (publ) maintains its headquarters in Lund, Sweden.
2026-06-01 21:04:05
BioInvent International AB (publ) (BOVNF) Discusses Ovarian Cancer Treatment Landscape and TNFR2-Targeted Therapies in Solid Tumors Transcript
2026-05-20 05:50:00
LUND, SE / ACCESS Newswire / May 20, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune‑modulatory antibodies, today announced that it will host a virtual key opinion leader (KOL) event on Wednesday, May 27, 2026 at 8:00 AM EDT / 2:00 PM CEST featuring Dmitriy Zamarin MD, PhD (Tisch Cancer Center, Icahn School of Medicine at Mount Sinai), who will join company management to discuss the unmet need and current treatment landscape for ovarian cancer. To register, click here.
Resolutions at BioInvent's Annual General Meeting 2026
2026-04-29 12:00:00
LUND, SE / ACCESS Newswire / April 29, 2026 / The Annual General Meeting (AGM) of BioInvent International AB (BioInvent) (Nasdaq Stockholm:BINV) resolved to elect Kate Hermans and Scott Zinober as new Board members, re-elect the Board members Natalie Berner, Leonard Kruimer, Nanna Lüneborg and Bernd Seizinger, and to implement, inter alia, a long-term incentive program. The AGM voted in favor of adopting the income statements and balance sheets for the Group and the parent company for the financial year 2025 and decided that no dividend should be declared for the financial year 2025.
BioInvent to Host Two Key Opinion Leader Events Highlighting Progress Across Oncology Portfolio
2026-04-29 05:55:00
Events will feature expert perspectives on BI-1808 in ovarian cancer and T‑cell lymphomas, and BI-1206 for the treatment of NHL LUND, SE / ACCESS Newswire / April 29, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune‑modulatory antibodies, will host two Key Opinion Leader (KOL) events in the coming weeks, highlighting scientific and clinical progress across its BI-1808 and BI-1206 programs. Virtual KOL Event: BI‑1808 for the treatment of solid tumors BioInvent will host a virtual KOL event focused on BI-1808, the Company's novel anti‑TNFR2 antibody, and its potential role in the treatment of ovarian cancer.
BioInvent International AB: Interim Report January - March 2026
2026-04-29 02:20:00
LUND, SE / ACCESS Newswire / April 29, 2026 / BioInvent International (STO:BINV) "During the first quarter of 2026, our strategy remained centered on efficient resource allocation across our most advanced assets, BI-1808 (anti-TNFR2) and BI-1206 (anti-FcγRIIB), with the goal of advancing these innovative immune-modulatory antibodies for patients who urgently need better treatment options."- Martin Welschof, CEO of BioInvent.
Frequently Asked Questions
-
What is the current BioInvent International AB (publ) (BOVNF) stock price?
-
BioInvent International AB (publ)(OTC:BOVNF) stock price is $3.2886 in the last trading session. During the trading session, BOVNF stock reached the peak price of $4.7 while $3.2886 was the lowest point it dropped to. The percentage change in BOVNF stock occurred in the recent session was 0.0% while the dollar amount for the price change in BOVNF stock was $0.
-
BOVNF's industry and sector of operation?
-
The OTC listed BOVNF is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of BOVNF?
-
Kristoffer Rudenholm Hansson | Senior Vice President of Technical Operations
Ingrid Teige | Head of Preclinical Research
Sylvie Ryckebusch | Chief Business Officer
Andres McAllister | Chief Medical Officer
Stefan Ericsson | Chief Financial Officer -
How many employees does BOVNF have?
-
Number of BOVNF employees currently stands at 114. BOVNF operates from The Gamma Building, Lund, SN 223 70, SE.
-
Link for BOVNF official website?
-
Official Website of BOVNF is: https://www.bioinvent.com
-
How do I contact BOVNF?
-
BOVNF could be contacted at phone #46 4 62 86 85 50 and can also be accessed through its website. BOVNF operates from The Gamma Building, Lund, SN 223 70, SE.
-
How many shares of BOVNF are traded daily?
-
The average number of BOVNF shares traded daily for last 3 months was 797.
-
What is the market cap of BOVNF currently?
-
The market value of BOVNF currently stands at $216.4M with its latest stock price at $3.2886